AGAndrew Geronimo

Andrew Geronimo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew Geronimo has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Feasibility of Longitudinal Home Monitoring of Nocturnal Transcutaneous CO 2 and Relationship to Standard Respiratory Measures in Patients With ALS : A Pilot Cohort Study

    by Andrew Geronimo, Quy Cao, Lauren Elman, Zachary Simmons, Jason Ackrivo

    Introduction/Aims: Amyotrophic lateral sclerosis (ALS) results in respiratory muscle weakness causing hypoventilation, retention of carbon dioxide (CO 2 ), and chronic hypercapnic respiratory failure. In this pilot study, we performed a 12‐month assessment of daytime and home nocturnal CO 2 to track respiratory progression, determine relationships with surrogate respiratory measures, and assess the impact of non‐invasive ventilatory support. Methods: Adults with forced vital capacity (FVC) less than 90% predicted secondary to ALS were recruited from two sites in the northeast US. Participants were followed up at standard visits every 3 months for up to five visits. Spirometry, functional scores, and patient‐reported outcomes of dyspnea were recorded. Each visit included a 15‐min, seated measurement of transcutaneous CO 2 (PtcCO 2 ) while in clinic, followed by 3 nights of home overnight PtcCO 2 monitoring. Linear mixed‐effects models were employed to describe the changes that occurred longitudinally and resulting from the initiation of non‐invasive ventilation (NIV). Results: Sixteen subjects were enrolled, with nine completing the full study. Strength and FVC declined over time, while daytime PtcCO 2 remained stable. Five individuals demonstrated nocturnal hypercapnia that preceded FVC < 50% predicted normal. Transition to NIV was associated with a 7 mmHg decrease in nocturnal PtcCO 2 . Discussion: Home nocturnal PtcCO 2 assessment in ALS may identify respiratory insufficiency prior to FVC. Transcutaneous CO 2 may play a role in the respiratory management of patients as a biomarker for hypoventilation risk and NIV titration. However, equipment availability and data quality limitations would benefit from professional assistance rather than independent in‐home use.

  • Graph Priors Improve Seizure Onset Zone Identification in a Graph Convolutional Network of StereoEEG

    by Baizhou Pan, Xiaoxiao Sun, Alain Zingraff Lekoubou Looti, Andrew Geronimo

  • Open Access

    A perspective on CO2 gas sensing — from environments to the skin interface

    by Md Abu Sayeed Biswas, Andrew Geronimo, Huanyu Cheng


  • Open Access

    Operating Room Personnel Perspectives on Sustainable Practices in the Operative Environment

    by Natasha Sood, Calista Long, Yuriy Pechenyy, Catherine Caldwell, Amanda Cooper, Andrew Geronimo

  • Open Access

    Using wearable sensors and machine learning to assess upper limb function in Huntington’s disease

    by Adonay S. Nunes, İlKay Yıldız Potter, Ram Kinker Mishra, Jose Casado, Nima Dana, Andrew Geronimo, Christopher G. Tarolli, Ruth B. Schneider, E. Ray Dorsey, Jamie L. Adams, et al.

    Background Huntington’s disease, a neurodegenerative disorder, impairs both upper and lower limb function, typically assessed in clinical settings. However, wearable sensors offer the opportunity to monitor real-world data that complements clinical assessments, providing a more comprehensive understanding of disease symptoms. Methods In this study, we monitor upper limb function in individuals with Huntington’s disease (HD, n = 16), prodromal HD (pHD, n = 7), and controls (CTR, n = 16) using a wrist-worn wearable sensor over a 7-day period. Goal-directed hand movements are detected through a deep learning model, and kinematic features of each movement are analyzed. The collected data is used to predict disease groups and clinical scores using statistical and machine learning models. Results Here we show that significant differences in goal-directed movement features exist between the groups. Additionally, several of these features strongly correlate with clinical scores. Classification models accurately distinguish between HD, pHD, and CTR individuals, achieving a balanced accuracy of 67% and a recall of 0.72 for the HD group. Regression models effectively predict clinical scores. Conclusions This study demonstrates the potential of wearable sensors and machine learning to monitor upper limb function in Huntington’s disease, offering a tool for early detection, remote monitoring, and assessing treatment efficacy in clinical trials.


  • Open Access

    A nurse coaching intervention to improve support to individuals living with ALS

    by Susan Walsh, Zachary Simmons, Sheridan Miyamoto, Andrew Geronimo

    Health coaching may supplement the multidisciplinary ALS clinic model to facilitate patient-centered health behavior change. The aim of this study was to determine the effects of nurse health coaching (NHC) on the quality of life and self-efficacy of individuals living with ALS. Twenty-nine participants were randomized at 1:1 to the standard of care and coaching arms. All participants attended multidisciplinary ALS clinic visits quarterly, at which times they completed assessments of quality of life and self-efficacy. Those in the coaching arm participated in monthly coaching with a nurse coach over 12 months. The coaching sessions utilized motivational interviewing to identify personal goals along with barriers and solutions to achieve them. Linear mixed-effect models were used to quantify the effect of coaching on quality of life and self-efficacy outcomes. Thematic analysis was performed to summarize the participants' experiences with coaching. Adherence to the coaching intervention was good. No effects of coaching were observed on the primary outcomes of quality of life and self-efficacy, although debriefed participants reported that they would recommend it to others. Patients and caregivers reflected on the impacts of coaching that extended beyond the pre-defined study outcomes and measures put in place to gauge effectiveness. The elicited qualitative themes illustrating patient experience of coaching demonstrate the utility of nurse coaching as an important adjunct support to complement the multidisciplinary ALS clinic model.


  • Open Access

    Using Wearable Sensors and Machine Learning to Assess Upper Limb Function in Huntington's Disease

    by Adonay S. Nunes, İlKay Yıldız Potter, Ram Kinker Mishra, Jose Casado, Nima Dana, Andrew Geronimo, Christopher G. Tarolli, Ruth B. Schneider, E. Ray Dorsey, Jamie L. Adams, et al.

    Huntington's disease (HD), like many other neurological disorders, affects both lower and upper limb function that is typically assessed in the clinic - providing a snapshot of disease symptoms. Wearable sensors enable the collection of real-world data that can complement such clinical assessments and provide a more comprehensive insight into disease symptoms. In this context, almost all studies are focused on assessing lower limb function via monitoring of gait, physical activity and ambulation. In this study, we monitor upper limb function during activities of daily living in individuals with HD (n = 16), prodromal HD (pHD, n = 7), and controls (CTR, n = 16) using a wrist-worn wearable sensor, called PAMSys ULM, over seven days. The participants were highly compliant in wearing the sensor with an average daily compliance of 99% (100% for HD, 98% for pHD, and 99% for CTR). Goal-directed movements (GDM) of the hand were detected using a deep learning model, and kinematic features of each GDM were estimated. The collected data was used to predict disease groups (i.e., HD, pHD, and CTR) and clinical scores using a combination of statistical and machine learning-based models. Significant differences in GDM features were observed between the groups. HD participants performed fewer GDMs with long duration (> 7.5 seconds) compared to CTR (p-val = 0.021, d = -0.86). In velocity and acceleration metrics, the highest effect size feature was the entropy of the velocity zero-crossing length segments (HD vs CTR p-val <0.001, d = -1.67; HD vs pHD p-val = 0.043, d=-0.98; CTR vs pHD p-val = 0.046, d=0.96). In addition, this same variable showed a strongest correlation with clinical scores. Classification models achieved good performance in distinguishing HD, pHD and CTR individuals with a balanced accuracy of 67% and a 0.72 recall for the HD group, while regression models accurately predicted clinical scores. Notably the explained variance for the upper extremity function subdomain scale of Unified Huntington’s Disease Rating Scale (UHDRS) was the highest, with the model capturing 60% of the variance. Our findings suggest the potential of wearables and machine learning for early identification of phenoconversion, remote monitoring in HD, and evaluating new treatments efficacy in clinical trials and medicine. *Jamie L. Adams and Ashkan Vaziri have contributed equally to this work as senior authors.


  • Open Access

    Sodium phenylbutyrate–taurursodiol access, adherence and adverse event in patients with amyotrophic lateral sclerosis: Experience at one center in the United States

    by Mansoureh Mamarabadi, Eleni Fafoutis, Andrew Geronimo, Susan Walsh, Zachary Simmons

    Introduction/Aims: Sodium phenylbutyrate–taurursodiol (PB‐TURSO) was recently approved for treating amyotrophic lateral sclerosis (ALS). Third‐party payors' coverage policies are evolving, and adverse events are just being fully assessed. The goals of this study were to evaluate patients' experiences in obtaining and continuing PB‐TURSO and assess adverse events and medication adherence.Methods: Medical records of 109 ALS patients who were considered PB‐TURSO candidates by the treating physician at a tertiary ALS clinic from October 2022 to May 2023 were reviewed. Data was recorded for demographics, clinical, and insurance information. A survey was e‐mailed to patients asking about out‐of‐pocket expenses for PB‐TURSO, financial assistance, medication start and (if applicable) stop dates, and reasons for discontinuation.Results: Insurance information was available for 91 patients [57 males (62%); mean age 64.8 years (range 25.7–88)]. Of 79 who applied for insurance approval, 71 (90%) were approved; however, 19 required 1–3 appeals. Among 73 patients with available data about medication status, 54 started PB‐TURSO and 19 did not, most commonly due to personal choice or out‐of‐pocket expenses. About 44% of patients (24/54) stopped taking PB‐TURSO, primarily due to adverse events. Monthly out‐of‐pocket expenses varied from $0 to $3500 and 36 patients qualified for financial assistance. Administrative and nursing staff devoted 7.2 hours/week to the insurance authorization process.Discussion: Most patients received insurance approval for PB‐TURSO, but one‐fourth required appeals. Some out‐of‐pocket costs were very high. Investment of staff time was substantial. These findings have implications for insurance coverage of, and adherence to, future ALS treatments.


  • Turning up the volume on neuromuscular cough medicine

    by Andrew Geronimo

    See article on pages 213–217 in this issue.